SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Exagen Inc. – ‘10-K’ for 12/31/20 – ‘EX-10.34’

On:  Tuesday, 3/16/21, at 5:22pm ET   ·   For:  12/31/20   ·   Accession #:  1274737-21-15   ·   File #:  1-39049

Previous ‘10-K’:  ‘10-K’ on 3/25/20 for 12/31/19   ·   Next:  ‘10-K/A’ on 4/1/21 for 12/31/20   ·   Latest:  ‘10-K’ on 3/18/24 for 12/31/23   ·   17 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/16/21  Exagen Inc.                       10-K       12/31/20   78:8.7M

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.21M 
 3: EX-10.25    Material Contract                                   HTML     33K 
 4: EX-10.34    Material Contract                                   HTML     31K 
 5: EX-10.46    Material Contract                                   HTML     99K 
 2: EX-10.5     Material Contract                                   HTML     42K 
 6: EX-23.1     Consent of Expert or Counsel                        HTML     21K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
16: R1          Cover                                               HTML     87K 
17: R2          Balance Sheets                                      HTML     90K 
18: R3          Balance Sheets - (Parenthetical)                    HTML     40K 
19: R4          Statements of Operations                            HTML     74K 
20: R5          Statements of Redeemable Convertible Preferred      HTML    113K 
                Stock and Stockholders' Equity                                   
21: R6          Statements of Redeemable Convertible Preferred      HTML     26K 
                Stock and Stockholders' Equity (Parenthetical)                   
22: R7          Statements of Cash Flows                            HTML    130K 
23: R8          Organization                                        HTML     26K 
24: R9          Summary of Significant Accounting Policies          HTML    109K 
25: R10         Other Financial Information                         HTML     53K 
26: R11         Borrowings                                          HTML     36K 
27: R12         Commitment and Contingencies                        HTML     41K 
28: R13         Fair Value Measurements                             HTML     36K 
29: R14         Redeemable Convertible Preferred Stock              HTML     25K 
30: R15         Stockholders' Equity                                HTML     35K 
31: R16         Stock Option Plan                                   HTML     66K 
32: R17         Income Taxes                                        HTML     73K 
33: R18         Related Parties                                     HTML     24K 
34: R19         401(k) Plan                                         HTML     27K 
35: R20         Covid-19                                            HTML     26K 
36: R21         Summary of Significant Accounting Policies -        HTML     89K 
                (Policies)                                                       
37: R22         Summary of Significant Accounting Policies -        HTML     84K 
                (Tables)                                                         
38: R23         Other Financial Information - (Tables)              HTML     57K 
39: R24         Borrowings - (Tables)                               HTML     29K 
40: R25         Commitment and Contingencies (Tables)               HTML     51K 
41: R26         Fair Value Measures and Disclosures (Tables)        HTML     35K 
42: R27         Stockholders' Equity (Tables)                       HTML     33K 
43: R28         Stock Option Plan (Tables)                          HTML     70K 
44: R29         Income Taxes (Tables)                               HTML     74K 
45: R30         Organization - (Details)                            HTML     27K 
46: R31         Summary of Significant Accounting Policies -        HTML     41K 
                Revenue by Major Payers (Details)                                
47: R32         Summary of Significant Accounting Policies -        HTML     96K 
                Narrative (Details)                                              
48: R33         Summary of Significant Accounting Policies -        HTML     36K 
                Disaggregation of Revenue (Details)                              
49: R34         Summary of Significant Accounting Policies - Cash,  HTML     30K 
                cash equivalents and restricted cash (Details)                   
50: R35         Summary of Significant Accounting Policies -        HTML     31K 
                Securities (Details)                                             
51: R36         Other Financial Information - Prepaid expenses      HTML     33K 
                (Details)                                                        
52: R37         Other Financial Information - Property and          HTML     40K 
                equipment (Details)                                              
53: R38         Other Financial Information - Narrative (Details)   HTML     28K 
54: R39         Other Financial Information - Accrued liabilities   HTML     40K 
                (Details)                                                        
55: R40         Borrowings - Narrative (Details)                    HTML     58K 
56: R41         Borrowings - Future minimum payments (Details)      HTML     40K 
57: R42         Commitment and Contingencies - Narrative (Details)  HTML     50K 
58: R43         Commitment and Contingencies - Minimum annual       HTML     66K 
                lease payments under non-cancelable lease                        
                arrangements (Details)                                           
59: R44         Fair Value Measurements (Details)                   HTML     31K 
60: R45         Redeemable Convertible Preferred Stock (Details)    HTML     47K 
61: R46         Stockholders' Equity - Narrative (Details)          HTML     40K 
62: R47         Stockholders' Equity (Details)                      HTML     38K 
63: R48         Stock Option Plan - Narrative (Details)             HTML     60K 
64: R49         Stock Option Plan - Stock Option Activity           HTML     76K 
                (Details)                                                        
65: R50         Stock Option Plan - Fair Value Assumptions          HTML     46K 
                (Details)                                                        
66: R51         Stock Option Plan - Stock-Based Compensation        HTML     31K 
                Expense (Details)                                                
67: R52         Stock Option Plan - Common Stock Reserved For       HTML     32K 
                Future Issuance (Details)                                        
68: R53         Income Taxes - Components of Income Tax Expense     HTML     44K 
                (Benefit) (Details)                                              
69: R54         Income Taxes - Reconciliation of Effective Income   HTML     38K 
                Tax Rate (Details)                                               
70: R55         Income Taxes - Reconciliation of Deferred Tax       HTML     51K 
                Assets and Liabilities (Details)                                 
71: R56         Income Taxes - Change In Valuation Allowance        HTML     27K 
                (Details)                                                        
72: R57         Income Taxes - Narrative (Details)                  HTML     33K 
73: R58         401(k) Plan (Details)                               HTML     25K 
74: R59         Covid-19 (Details)                                  HTML     33K 
76: XML         IDEA XML File -- Filing Summary                      XML    132K 
15: XML         XBRL Instance -- exdx-20201231_htm                   XML   1.42M 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX     91K 
11: EX-101.CAL  XBRL Calculations -- exdx-20201231_cal               XML    230K 
12: EX-101.DEF  XBRL Definitions -- exdx-20201231_def                XML    566K 
13: EX-101.LAB  XBRL Labels -- exdx-20201231_lab                     XML   1.63M 
14: EX-101.PRE  XBRL Presentations -- exdx-20201231_pre              XML    918K 
10: EX-101.SCH  XBRL Schema -- exdx-20201231                         XSD    158K 
77: JSON        XBRL Instance as JSON Data -- MetaLinks              371±   546K 
78: ZIP         XBRL Zipped Folder -- 0001274737-21-000015-xbrl      Zip    710K 


‘EX-10.34’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 10.34
FIRST AMENDMENT OF LEASE

This First Amendment of Lease is made on December 30, 2020, between Liberty Vista, a California limited partnership, ("Lessor"), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., ("Lessee"), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows:

1.Recitals. This First Amendment of Lease is made with reference to the following facts and objectives:
a.Lessor and Lessee entered into a written Lease dated August 15, 2014, as extended February 1, 2018, and as extended February 25, 2020 ("the Lease") in which Lessor leased to Lessee, and Lessee leased from Lessor, premises located in the City of Vista, County of San Diego, California, commonly known as 1221 Liberty Way, Vista, CA 92083, consisting of approximately 19,504 square feet ("Premises").
b.The term of the Lease expires on January 31, 2026.
c.The parties desire to amend the Base Rent Schedule to include amortization of the additional tenant improvement allowance.
2.Tenant Improvement Allowance. Lessee used its "Additional Allowance" of Fifty Thousand Dollars ($50,000.00) and was reimbursed for the same by Lessor. Pursuant the terms of the Lease the $50,000 additional allowance shall be amortized at 7% annual interest over the remaining term and paid monthly by Lessee as additional Base Rent (as shown in the Base Monthly Rent Schedule below).
3.Base Monthly Rent Schedule.
TermBase Rent
Additional Base Rent (Amortized TIA)
Total Base Rent
February 1, 2021 through January 31, 2022$19,000.00 $990.00 $19,990.00 
February 1, 2022 through January 31, 2023$19,600.00 $990.00 $20,590.00 
February 1, 2023 through January 31, 2024$20,200.00 $990.00 $21,190.00 
February 1, 2024 through January 31, 2025$20,800.00 $990.00 $21,790.00 
February 1, 2025 through January 31, 2026$21,400.00 $990.00 $22,390.00 
4.Effectiveness of Lease. Except as set forth in this First Amendment of Lease, all the provisions of the Lease shall remain unchanged and in full force and effect.



LESSOR:LESSEE:
Liberty VistaExagen Diagnostics, Inc.
A California Limited Partnership
By: Hamann Property Management, Inc.
Authorized Agent
By: /s/ Brendan ThiessenBy: /s/ Fortunato Ron Rocca
Brendan Thiessen - Asset ManagerFortunato Ron Rocca, President & CEO
Date: 1/6/2021Date: 1/6/2021



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
1/31/26
2/1/25
1/31/25
2/1/24
1/31/24
2/1/23
1/31/23
2/1/22
1/31/22
Filed on:3/16/218-K
2/1/21
For Period end:12/31/2010-K/A
12/30/20
2/25/20
2/1/18
8/15/14
 List all Filings 


11 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/13/24  Exagen Inc.                       S-8         5/13/24    4:130K
 3/18/24  Exagen Inc.                       10-K       12/31/23   76:8.9M
 5/18/23  Exagen Inc.                       S-8         5/18/23    4:132K
 3/20/23  Exagen Inc.                       10-K       12/31/22   76:9.1M
 5/11/22  Exagen Inc.                       S-8         5/11/22    4:128K
 3/22/22  Exagen Inc.                       10-K       12/31/21   73:8.6M                                   Workiva Inc Wde… FA01/FA
 5/11/21  Exagen Inc.                       S-8         5/11/21    3:135K
 5/11/21  Exagen Inc.                       10-Q        3/31/21   59:5M
 4/01/21  Exagen Inc.                       10-K/A     12/31/20   14:498K
 3/23/21  Exagen Inc.                       424B5                  1:601K                                   Donnelley … Solutions/FA
 3/22/21  Exagen Inc.                       424B5                  1:599K                                   Donnelley … Solutions/FA


6 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/10/20  Exagen Inc.                       10-Q        9/30/20   62:5.7M
 7/28/20  Exagen Inc.                       10-Q        6/30/20   62:6.3M
 3/25/20  Exagen Inc.                       10-K       12/31/19   88:11M
 9/23/19  Exagen Inc.                       8-K:5,8,9   9/23/19    3:227K                                   Donnelley … Solutions/FA
 9/09/19  Exagen Inc.                       S-1/A                 12:4.2M                                   Donnelley … Solutions/FA
 8/23/19  Exagen Inc.                       S-1                   51:8.5M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001274737-21-000015   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 2:23:03.1pm ET